CDK14 and synucleinopathy: Further in vivo experiments will test whether CDK14 inhibition rescues PD-like neuron loss and behavioral phenotypes in models of synucleinopathies; elucidating the potential of targeting CDK14 as a therapeutic strategy for PD patients.